Breast Cancer Therapeutics Market Is Expected To Witness Growth in North America

The rising prevalence of breast cancer around the globe is predominantly influencing the growth of the breast cancer therapeutics market. According to Breast Cancer Organization, an estimated 252,710 new cases of breast cancer are expected to be identified in the U.S., of which 63,410 cases would be non-invasive breast cancer in 2017. In the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer among women. Moreover, Epidemiologists predict that the established incident cases of breast cancer in women will grow over the following decade to reach 949,161 cases in 2025. The advent of innovative therapy with improved success rate is expected to provide lucrative growth opportunities in the near future.

In July 2019, Eisai Co., Ltd., a Japanese pharmaceutical company, received New Drug Approval for its anticancer agent Halaven (eribulin mesylate) from China National Medical Products Administration (NMPA), which is indicated for the use people suffering from metastatic or locally advanced breast cancer
In August 2019, Roche AG received product approval for Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) from European Commission. This is indicated for the patients with metastatic or unresectable locally advanced triple-negative breast cancer.

Breast cancer therapy involves the use of various drugs or a combination of drugs in treating different breast cancers. This breast cancer therapy can either be in the form of hormonal therapy, or radiotherapy, or chemotherapy.

Globally, there is a huge demand for quality breast cancer therapy with more research efforts going in for newer and better methods of treating breast cancer. Therapeutic approaches for the different types of breast cancer include hormone replacement therapy, surgery, radiation therapy, and targeted drug therapy. The targeted drug therapy includes breast cancer medications like tamoxifen, and hgh, or platinum compounds. Similarly, chemotherapy drugs like cisplatin, vincristine, doxorubicin, carboplatin vinorelbine, etc are used to treat advanced or stage I cancers.

Coherent Market Insights celebrating 5th anniversary and offering 1000 USD off for all reports. Let’s celebrate with us.
Click for promo code: https://www.coherentmarketinsights.com/promo/buynow/250

North America is expected to dominate the global breast cancer therapeutics market owing to the high prevalence rate of breast cancers in the region. Moreover, key players are engaged in adopting various business strategies such as research and development in the region. For instance, in July 2019, Eli Lilly and Company, a U.S.-based pharmaceutical company, announced positive results for Verzenio (abemaciclib), which demonstrated significant improvement in overall survival of Phase 3 MONARCH 2 clinical trial. Verzenio is indicated for the treatment of advanced or metastatic breast cancer.

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/breast-cancer-therapeutics-market-250

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

About Us:
Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. The company’s client base includes players from across various business verticals in over 47 countries globally. It takes pride in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and start-ups looking to establish a foothold in the market.

This release was published on openPR.